Related Experiment Video
Updated: Aug 15, 2026

Assessing Murine Resistance Artery Function Using Pressure Myography
Published on: June 7, 2013
Hypertension and nephropathy
1Hypertension Clinical Research Center, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612, USA.
Insights
Many patients with hypertension and diabetes struggle to control blood pressure. Thiazolidinediones (TZDs) show promise in improving insulin resistance and vascular health, potentially reducing complications.
Area of Science:
- Cardiology
- Endocrinology
- Nephrology
Background:
- Hypertension and diabetes mellitus significantly increase cardiovascular and renal complication risks.
- Most patients with both conditions do not achieve target systolic blood pressure (<130 mm Hg).
- Renin-angiotensin system inhibitors and diuretics may help reduce blood pressure and slow nephropathy progression.
Purpose of the Study:
- To explore the role of thiazolidinediones (TZDs) in managing hypertension and diabetes.
- To investigate the vascular benefits of TZDs in type 2 diabetes patients.
- To assess the impact of TZDs on glucose control, microalbuminuria, and hypertension.
Main Methods:
- Review of recent studies on thiazolidinediones (TZDs) in type 2 diabetes.
- Analysis of TZD effects on insulin resistance, vascular function, and blood pressure.
- Examination of TZD association with microalbuminuria and hypertension development.
Main Results:
- TZDs improve insulin resistance and offer vascular benefits like vasorelaxation and reduced inflammation.
- These vascular effects are linked to blood pressure reduction and microalbuminuria prevention.
- Early TZD use may aid glucose control and mitigate microalbuminuria and hypertension.
Conclusions:
- TZDs demonstrate potential benefits for patients with type 2 diabetes and hypertension.
- Their use may improve glycemic control and reduce cardiovascular and renal complications.
- Further research supports TZDs as a valuable therapeutic option in this patient group.
Abstract:
Nearly 90% of patients with hypertension and diabetes mellitus do not reach the recommended systolic blood pressure goal of <130 mm Hg. Consequently, the risk of cardiovascular and renal complications remains significant in this patient population. Study results suggest that initiating therapy with inhibitors of the renin-angiotensin system and adding diuretics may be useful in reducing arterial pressure to levels <130 mm Hg and may attenuate the progression of nephropathy. Recently, numerous studies have also found that the thiazolidinediones (TZDs) may improve insulin resistance and exert beneficial vascular effects in patients with type 2 diabetes. The TZDs have a range of vascular benefits, including mediating vasorelaxation, inhibiting angiogenesis, and improving inflammation. These findings have been associated with reduction in blood pressure and prevention of microalbuminuria. In patients with type 2 diabetes, early use of TZDs may be beneficial in both achieving glucose control and reducing the development or worsening of microalbuminuria or hypertension.
Related Concept Videos
Hypertension and Regulation of Blood Pressure
Hypertension I: Introduction
Hypertension II: Pathophysiology
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension V: Nursing Management
Diabetic Nephropathy

